Mark H F, Taylor W, Afify A, Riera D, Rausch M, Huth A, Gray Y, Santoro K, Bland K I
Department of Pathology, Rhode Island Hospital, Providence 02903, USA.
Pathobiology. 1997;65(4):184-9. doi: 10.1159/000164121.
We previously reported the results of 30 informative samples (from a total of 34 specimens gathered) of archival breast cancer tissue, including infiltrating ductal carcinoma (NOS), ductal carcinoma in situ, lobular carcinoma, papillary carcinoma and benign lesions of the breast. The study was conducted using fluorescent in situ hybridization (FISH) and a chromosome 8 alpha-satellite probe. Subsequently, a total of 34 cases of infiltrating ductal carcinoma of the breast (NOS, 17 cases stage I and 17 cases stage II) were studied, again using interphase cytogenetics. The aim of the present study is to confirm and extend the results of our initial study of stage I and stage II disease. Towards this end, 36 additional specimens of formalin-fixed paraffin-embedded breast cancer tissue have been analyzed cytogenetically under blinded conditions for the frequency of abnormal chromosome 8 copy numbers using FISH and the previously described protocol optimized for our laboratory. Of these, 18 were stage I and 18 were stage II. The frequency of trisomy 8 among stage I tumors was found to be 28% (5 out of 18). The frequency of trisomy 8 among stage II tumors was found to be 61% (11 out of 18). These results, while less striking, are consistent with those reported in our initial study of stage I and stage II disease, where the frequencies of trisomy 8 among stage I and stage II tumors were 24% (4 out of 17) and 82% (14 out of 17). These results not only establish that chromosome 8 trisomy is a recurrent finding in breast cancer, but also confirm that a higher frequency of trisomy 8 was observed with a higher clinical stage (stage II) than with a lower stage (stage I). It will be of interest to extend the findings in stage I and stage II breast cancer to other stages as well.
我们之前报告了30份有参考价值的样本（取自总共收集的34份标本）的存档乳腺癌组织检测结果，包括浸润性导管癌（非特殊型）、原位导管癌、小叶癌、乳头状癌以及乳腺良性病变。该研究采用荧光原位杂交（FISH）技术和8号染色体α卫星探针进行。随后，又对总共34例乳腺浸润性导管癌（非特殊型，17例I期和17例II期）进行了研究，同样采用间期细胞遗传学方法。本研究的目的是确认并扩展我们对I期和II期疾病初步研究的结果。为此，在盲法条件下，使用FISH和我们实验室优化的前述方案，对另外36份福尔马林固定石蜡包埋的乳腺癌组织标本进行了细胞遗传学分析，以检测8号染色体异常拷贝数的频率。其中，18例为I期，18例为II期。I期肿瘤中8号染色体三体的频率为28%（18例中有5例）。II期肿瘤中8号染色体三体的频率为61%（18例中有11例）。这些结果虽然不那么显著，但与我们对I期和II期疾病的初步研究报告结果一致，在该研究中，I期和II期肿瘤中8号染色体三体的频率分别为24%（17例中有4例）和82%（17例中有14例）。这些结果不仅证实8号染色体三体在乳腺癌中是一个常见发现，还确认II期（较高临床分期）比I期（较低临床分期）观察到更高频率的8号染色体三体。将I期和II期乳腺癌的研究结果扩展到其他分期也将是有意义的。
